Conference abstractPublished 26 Sep 2016
PDGFRα signaling strength confers sensitivity to Vinblastine in glioblastoma
Beth Israel Deaconess Medical Center, USA Harvard Medical School, USA Tufts University School of Medicine, USA Tufts Medical Center, USA Mayo Clinic, USA Dana-Farber Cancer Institute, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The PDGF Receptor alpha is overexpressed and activated in a substantial number of Glioblastoma (GBM) tumors. Although the activation of PDGFRÃ?± in GBM is chronic in nature, our knowledge of PDGFR signaling pathways is largely derived from acute stimulation studies, which are less representative of the clinical setting. In order to decipher the identity and clinical significance of sustained PDGFRÃ?± signaling during tumorigenesis and to reveal therapeutic vulnerabilities, we created a novel genetically engineered conditional mouse model based on genomic events that are observed in patients, that is the overexpression of PDGFRÃ?± and its chronic activation by PDGF-A ligand in the context of loss of function of the p53 tumor suppressor gene. To broaden its clinical relevance, we created our model system with a titratable expression of PDGF-A, which is specific for PDGFRÃ?± homodimers. De novo intracranial PDGF-A;PDGFRÃ?± tumors arise in these mice with full penetrance and short latency and display histological and molecular features that are consistent with Proneural GBMs. Tumor growth in animals was intimately related to the levels of PDGF-A ligand expression, suggesting differences in cellular signaling in tumors with low and high levels of activated receptors. Indeed, global phospho- (pTyr, pSer/pThr) and total proteomic analyses on cells derived from PDGFRÃ?±-positive GBMs revealed that the strength and utilization of specific signaling pathways are dependent on the levels of PDGFRÃ?± activation. Further investigation of these pathways unveiled a role for the microtubule binding protein Stathmin 1 (STMN1) in the vulnerability of these GBM cells to the microtubule-disrupting drug vinblastine. Our results open the possibility that GBM patients whose tumors express active PDGFRÃ?± could benefit from treatments with vinca alkaloid type of therapeutic agents. Our observations also argue strongly for the development of inhibitors of STMN1 function for the treatment of PDGFRÃ?± positive GBMs.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Alain Charest”
- BylineArticles whose byline prints “Vicky Appleman”
- BylineArticles whose byline prints “Christopher Rose”
- BylineArticles whose byline prints “Hua-Jun Wu”
- BylineArticles whose byline prints “Alan Yeo”
- BylineArticles whose byline prints “Bethany Delcuze”
- BylineArticles whose byline prints “Jesse Lyons”
- BylineArticles whose byline prints “Charlotte Lee”
